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Abstract
To compare long-term overall survival (OS) in patients with G1 and G2 grade Ta bladder cancer after transurethral resection of
bladder tumors (TURBTs). Secondary aim was to investigate clinical and pathologic prognostic factors for OS of Ta patients, except
G3/high grade (HG).
A total of 243 patients, retrospectively selected, with Ta nonmuscle invasive bladder cancer (NMIBC) underwent TURBT between
January 2006 and December 2008 (median follow-up 109 months). Inclusion criteria were: Ta at first manifestation, G1 or G2 grade
with no associated carcinoma in situ (CIS). Seventy-nine patients were excluded due to concomitant CIS (1), G3/HG tumors (47), and
lost to follow-up (31). Ethical approval was obtained from the Ethical Committee of theMures County Hospital. Statistical analysis was
performed using STATA 11.0.
Following inclusion criteria, 164 patients with primary G1 or G2 Ta tumors, were enrolled. Recurrence was observed in 26 (15.8%)
and progression in 5 (3%) patients. Ten-year survival in G1 patients was 67.8% (CI 54.3–78.1) and in G2 patients 59% (CI 49–67.3)
(P= .31). Univariable and multivariable logistic regression analysis underlined that advanced age at diagnosis (hazard ratio [HR] 1.10)
and no Bacillus Calmette–Guerin (BCG) treatment (HR 0.24 and 0.29) were independent predictors for death at 10 years after
diagnosis.
Long-term analysis confirms that patients with well differentiated (G1) and moderately well differentiated (G2) Ta tumors have
similar OS. A longer OS was even reported in those who underwent BCG adjuvant therapy.
Abbreviations: BC = bladder cancer, BCG = Bacillus Calmette–Guerin, CIS = carcinoma in situ, EORTC = The European
Organization for Research and Treatment of Cancer, HG = high grade, HR = hazard ratio, LG = low grade, MIBC =muscle invasive
bladder cancer, NMIBC = nonmuscle invasive bladder cancer, OS = overall survival, TURBT = transurethral resection of bladder
tumor, WHO = World Health Organization.
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11. Introduction
Bladder cancer (BC) is one of the most common of the urinary
tract, occupying the 2nd place after prostate cancer.[1] Approxi-
mately half of these newly diagnosed tumors are low grade
(LG)[2] and >70% are nonmuscle invasive bladder cancer
(NMIBC).[3] Themain procedure for the diagnosis and treatment
of NMIBC is the transurethral resection of bladder tumor
(TURBT) and according to the latest version of the European
Association of Urology guidelines, “an immediate chemotherapy
instillation is recommended in tumors presumed to be at low or
intermediate risk.”[2] Low-risk tumors are considered primary,
solitary, TaG1 (papillary urothelial neoplasm of low malignant
potential, LG), and <3cm, with no carcinoma in situ (CIS).
Intermediate risk tumors are those that do not fit to low category
or in any of the following: T1 tumor, G3 (high grade [HG])
tumor, and CIS; or recurrent and large (>3cm) TaG1G2/LG
tumors (all features must be present).[3]
Although NMIBC is a nonmuscle invasive tumor, it is well
known for its high risk of recurrence and progression. The
European Organization for Research and Treatment of Cancer
(EORTC) introduced a scoring system for calculating the
probability of recurrence and progression of these patients.[4]
To our knowledge, in terms of overall survival (OS), it has not
been yet published any long-term comparison between well
Balan et al. Medicine (2018) 97:16 Medicinedifferentiated (G1) and moderately well differentiated (G2)
(according to 1973 World Health Organization [WHO] system)
Ta tumors. Many large cohorts studies analyzing the long-term
survival of NMIBC patients in general after TURBT and
intravesical chemotherapy,[5,6] survival range varies between
studies but are mostly higher than in muscle-invasive bladder
cancer (MIBC).[7]
The main aim of the study was to compare the long-term OS in
patients with well-differentiated (G1) and moderately well
differentiated (G2) grade Ta BC after TURBT. The secondary
aimwas to investigate clinic and pathologic prognostic factors for
OS of these patients.Figure 1. Histological grading according to World Health Organization (WHO)
1973 grading system: (A) G1: transverse section of a papilla; thickened
urothelium with slender fibrovascular core; uniform elongated nuclei with
preserved nuclear polarity and differentiation to the surface, no mitosis; (B) G2:
moderately altered polarity, larger nuclei, variable in size, dense or irregular
nuclear chromatin; visible nucleoli; somemitosis can be identified; (C) G3: deep
architectural disorganization and severe nuclear atypia; coarse chromatin;
massive cellular desquamation.2. Methods
All patients with Ta NMIBC that underwent TURBT in the
urology department from TirguMures –Romania, within 3 years
between January 2006 and December 2008, have been enrolled.
Ethical approval was obtained from the Ethical Committee of the
Mures County Hospital. Inclusion criteria were: primary Ta, G1,
and G2 with nonassociated in situ carcinoma are classified as low
and intermediate tumors according to European Association of
Urology guidelines. Exclusion criteria were: any recurrent or
progressed cancer, any T1 and/or G3/HG tumor, any concomi-
tant CIS, and all cases of lost follow-up. EORTC risk scores were
calculated for each patient; EORTC risk tables allow to estimate
the probability of recurrence and progression based on a number
of tumors, tumor size, prior recurrence rate, T category,
concomitant CIS, and grade.[8]
Histological classification was done according to 1973 WHO
classification (Fig. 1). Recurrencewas defined as disease recurrence
at more than 3 months postoperatively, and progression was
considered the evolution ofHGT1 tumors orMIBC. According to
European Association of Urology guidelines, intravesical immu-
notherapy with Bacillus Calmette–Guerin (BCG) was administrat-
ed for intermediate risk Ta tumors, following the Lamm scheme: 1
weekly instillation for 6weeks, followed by3 years ofmaintenance
instillation with 3 weekly instillation every 3 or 6 months.[9–11]
Follow-up was made by clinical examination and cystoscopy at 3
months in the first 2 years and another cystoscopy at 6 months in
the next 3 years and then annually after that. Firstly, end-pointwas
set at the time until the first recurrence; secondly, end-point was
timeduntil progression, and thirdly end-pointwas the death of any
cause (from National Health Insurance Registry).
2.1. Statistical analysis
Data were labeled as nominal or quantitative variables. Nominal
variables were characterized using frequencies. Quantitative
variables were tested for normality of distribution by applying the
Kolmogorov–Smirnov test and were described by mean±
standard deviation or median and quartiles. The frequencies of
nominal variables were compared with the chi-square test and
Student t test was used to assess the differences between means of
continuous variables (expressed as mean±SD), while differences
between nonparametric variables (expressed as median, range)
were compared using the Mann–Whitney U test. Survival
analysis was performed using the Kaplan–Meyer method, and
the log-rank test was used for univariate comparisons.
Univariable and multivariable Cox regression models addressed
the association of prognostic factors with OS after TURBT.
Logistic regression analyses were performed to identify predictors
for 10-year OS. All P values were 2-sided, and statistical2significance was defined as a P< .05. Statistical analyses were
performed using Stata 11.0 statistical software (Stata Corp.,
College Station, TX).3. Results
A total of 243 patients, with G1 and G2 Ta tumors, have been
included and 164 met inclusion criteria. Seventy-nine patients
[1]
Table 1
Characteristics of 164 patients with low and intermediate grade Ta
bladder tumors at diagnosis.
Patients
characteristics No patients, % G1 G2 P
Age
Mean 63.3 y 62.9 y 63.6 y .71
Gender
Male 135 (82.3%) 45 (76.3%) 90 (85.7%) .12
Female 29 (17.7%) 14 (23.7%) 15 (14.3%)
Tu diameter
<3cm 78 (47.6%) 34 (57.6%) 44 (41.9%) .053
>3cm 86 (52.4%) 25 (42.4%) 61 (58.1%)
No tumors
Single 86 (52.4%) 32 (54.2%) 54 (51.4%) .73
Multiple (2–7) 78 (47.6%) 27 (45.8%) 51 (48.6%)
Grade
G1 59 (36%)   
G2 105 (64%)   
BCG treatment
No 132 (80.5%) 45 (76.3%) 87 (82.8%) .30
Yes 32 (19.5%) 14 (23.7%) 18 (17.2%)
Rec EORTC score
0 26 (15.8%) 26 (44.1%) 0 <.001∗
1–4 99 (60.4%) 17 (28.8%) 82 (78.1%)
5–9 39 (23.8%) 16 (27.1%) 23 (21.9%)
Prog EORTC score
0 57 (34.8%) 26 (44%) 31 (29.5%) .06
1–6 107 (65.2%) 33 (56%) 74 (70.5%)
Recurrence 26 (15.8%) 13 (22%) 13 (12.4%) .10
Progression 5 (3%) 3 (5%) 2 (1.9%) .25
Deaths 62 (37.8%) 19 (32.2%) 43 (41%) .26
BCG=Bacillus Calmette–Guerin, CI=confidence interval, EORTC=The European Organization for
Research and Treatment of Cancer, HR=hazard ratio.
Table 2
Association of clinico-pathologic factors with overall survival.
Death
Patients characteristics No (102 patients) Yes (62 patients) P
Age mean 59.8y 69 y <.001∗
Gender male (no/%) 83 (61.5) 52 (38.5) .68
Female 19 (65.5) 10 (34.5)
Tu diameter <3cm (no/%) 51 (65.4) 27 (34.6) .42
>3cm 51 (59.3) 35 (40.3)
No tumors single (no/%) 57 (66.3) 29 (33.7) .25
2–7 (no/%) 45 (57.7) 33 (42.3)
Grade G1 (no/%) 40 (67.8) 19 (32.2) .26
G2 (no/%) 62 (59) 43 (41)
BCG treatment no (no/%) 75 (56.8) 57 (43.2) .004∗
Yes (no/%) 27 (84.4) 5 (15.6)
Recurrence EORTC score 0 (no/%) 17 (65.4) 9 (34.6) .93
1–4 (no/%) 61 (61.6) 38 (38.4)
5–9 (no/%) 24 (61.5) 15 (38.5)
Progression EORTC score 0 (no/%) 40 (70.3) 17 (29.8) .12
1–6 (no/%) 62 (57.9) 45 (42.1)
Recurrence no (no/%) 87 (63) 51 (37) .6
Yes (no/%) 15 (57.7) 11 (42.3)
Progression no (no/%) 101 (63.5) 58 (36.5) .04∗
Yes (no/%) 1 (20) 4 (80)
BCG=Bacillus Calmette–Guerin, EORTC=The European Organization for Research and Treatment of
Cancer.
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lost of follow-up, and no data about 10-year survival.[31] Patients
were followed in average 109months (IQR 70–121months). The
mean age at diagnosis was 63.3 years (range 21–89) and 135
(82.3%) patients were males. Multiple tumors were observed in
78 (47.6%) cases, in 86 (52.4%) cases the diameter of tumor was
>3cm, G2 tumors were observed in 105 (64%) patients.
Intravesical immunotherapy with BCG was administrated in
32 (19.5%) patients according to guidelines recommendations at
that time (intermediate risk Ta tumors) as was the only available
adjuvant therapy following TURBT. Most patients had EORTC
recurrence score of 1 to 4: 99 (60.4%). Progression EORTC score
of 1 to 6 was observed in 107 (65.2%) patients. Recurrence was
observed in 26 (15.8%) and progression in 5 (3%) patients. At 10
years after diagnosis, a total of 102 patients (62.2%) were
survivors (Table 1).
Table 2 presents the association between clinicopathological
features and OS in the studied cohort. Looking at deaths,
advanced age at diagnosis was associated with lower OS: 69
versus 59.8 years mean age, respectively, in survivals (P< .001).
Mortality was higher in males (38.5%) than in females (34.3%)
but not statistically significant (P= .68). Even if not significant,
the survival rate was higher in G1 (67.8%) compared to G2
(59%) patients (P= .26). BCG treatment was associated with
higher survival 84.4% versus 56.8%, P= .004.
Univariable Cox analysis showed that predicting factors for OS
were the advanced age with a hazard ratio (HR) of 1.07; no BCG
treatment HR 0.30 and progression during follow-up HR 5.25.
Multivariable Cox analysis showed that independent predictors3forOSwere: age (HR 1.07); EORTC recurrence scores 1 to 4 (HR
0.23); EORTC recurrence scores 5 to 9 (HR 0.17); and
progression (HR 5.18) (Table 3).
Univariable and multivariable logistic regression analysis
underlined that the advanced age at diagnosis (HR 1.10) and
no BCG treatments (HR 0.24 and 0.29) were independent
predictors for death at 10 years after diagnosis (Table 4).
Kaplan–Meier survival analysis showed that there is 8%
difference in the survival between G1 and G2 grade, but with no
statistical significance. Five years survival was 86.4% (CI 74.7–
93) in G1 patients and 84.7% (CI 76.3–90.3) in G2 patients; 10
years survival was 67.8% (CI 54.3–78.1) in G1 patients and 59%
(CI 49–67.3) in G2 patients (Fig. 2A, P= .31). BCG treatment had
a benefit on the OS; 5 years OS was 82.6% (CI 74.9–88) in non-
BCG treated patients, and 96.8% (CI 79.8–99) in BCG treated
patients, respectively. Ten years OS was 56.8% (CI 47.9–64.7) in
non-BCG treated patients, and 84.4% (CI 66.4–93.1) in BCG
treated patients, P= .006 (Fig. 2B).
4. Discussion
We evaluated the long-term survival of 164 Ta G1-G2 NMIBC
patients in a single center with a median follow-up of 109
months. At 10 years after diagnosis, 62% of patients were
survivors. To make it easy to understand, we demonstrated that
advanced age at diagnosis was associated with worse OS and that
there is no statistical significance regarding 10-year OS between
patients with TaG1 compared with TaG2 patients. More
interestingly was the statistically significant relationship that
we found between BCG treatment and longer OS.
In 2009 Truls Gårdmark et al[12] published the Sweden data
regarding NMIBC. Several similarities could be observed in our
study. They showed that Ta cancer is more common in men, but
suggesting that this data may change because, in Sweden,
cigarette smoking is decreasing among men and is now equally
prevalent among women. They analyzed the data from 6 health
Table 3
Univariable and multivariable Cox regression analyses predicting overall survival of 164 patients with low and intermediate Ta bladder
cancer.
Univariable Multivariable
Prognostic factor HR 95% CI P HR 95% CI P
Age cont 1.07 1.04–1.10 <.001∗ 1.07 1.03–1.10 <.001∗
Gender 0.93 0.47–1.83 .84 0.82 0.40–1.68 .60
Multifocality 1.29 0.78–2.13 .31 1.90 0.81–4.43 .13
Diameter 1.26 0.76–2.08 .36 1.18 0.49–2.81 .70
Grade 1.31 0.76–2.25 .32 1.75 0.79–3.83 .16
EORTC rec Ref.
1–4 score 1.08 0.52–2.24 .82 0.23 0.06–0.91 .036∗
4–9 score 1.06 0.46–2.42 .89 0.17 0.03–0.76 .02∗
EORTC prog 1–6 score 1.52 0.87–2.67 .13 1.85 0.52–6.56 .33
BCG treatment (no treat) 0.3 0.12- 0.79 .01∗ 0.40 0.15–1.05 .063
Recurrence 1.28 0.67–2.46 .44 1.16 0.48–2.77 .72
Progression 5.25 1.89–14.57 <.001∗ 5.18 1.33–20.18 .018∗
BCG=Bacillus Calmette–Guerin, CI= confidence interval, EORTC=The European Organization for Research and Treatment of Cancer, HR=hazard ratio.
Balan et al. Medicine (2018) 97:16 Medicinecare institutions, stating that tumor grading significantly differed
between institutions. This information suggests that tumor
grading highly depends on the local histopathologist.
In 2016 Hernández et al[13] published an interesting paper on
active surveillance in case of well selected NMIBC patients
(especially TaG1), but still, experts and guidelines consider that
active surveillance should be definitively abandoned for BC and
banished from daily practice without further investigation.[14]
Several studies have highlighted the importance of adjuvant
therapy in improving long-term oncologic outcomes of
NMIBC,[15–20] resulting in higher recurrence-free survival
(RFS) with the usage of BCG compared to Epirubicin[16] but
no statistical difference between BCG and Mitomycin-C was
reported.[21]
Gupta and Parr examined a large cohort of NMIBC and
concluded that large size of tumors is not a negative prognostic
factor for patients with NMIBC and that pT1G2 should be
considered high-risk tumors,[22] with a median follow-up of 60
months, however, the study lacks data regarding OS.
Multiple tumors are considered as a risk factor for tumor
recurrence and worsening progression according to Kobayashi
et al[23]; lung cancer, hematuria, and >60 pack-years smoking
history according to Starke et al.[24] In line with Herr et al[24] in
our study, advanced age, lack of adjuvant therapy, and
progression proved to be statistically independent prognostic
factors. We also proved that advanced age is an independentTable 4
Univariable and multivariable logistic regression predicting overall su
Univariable
Prognostic factor HR 95% CI








EORTC prog 1.70 0.86–3.38
BCG treatment 0.24 0.08–0.67
BCG=Bacillus Calmette–Guerin, CI= confidence interval, EORTC=The European Organization for Rese
4prognostic factor. At 5 years, 27% of patients older than 70 years
were cancer-free compared to 37% who were younger than
70 years, including high-risk NMIBC patients.[25]
Thinking about the future predictive models, to better
understand urothelial neoplasm behavior and to better under-
stand recurrence and progression multiple biomarkers have been
studied as predictors for NMIBC patients outcomes,[26] the
closest to be embraced in clinical practice is neutrophil-to-
lymphocyte ratio, which is accessible and a less costly
biomarker.[27] Elevated neutrophil-to-lymphocyte ratio was
demonstrated to be an independent predictor for poor OS,
cancer-specific survival, recurrence, and progression in BC
patients.[28]
Data regarding long-term (at least 10 years) OS after initial
diagnosis of Ta BCa lack in the literature. In a UK study, OS
for Ta patients was 54% at 10 years,[29] on the other hand,
OS in high-risk NMIBC patients that received BCG or
Mytomicin C was 44% at 10 years.[21] Librenjak et al[18]
showed, in a cohort of NMIBC, that there is no significant
difference in OS between patients with BCG treatment (56%
10 years OS) and patients without BCG treatment (44% OS at
10 years). In a large multicenter cohort of TaG1 patients, the
estimated OS at 5 years was 86%,[30] (similar to our study,
where OS of TaG1 at 5 years was 86.4%) but more than half
of the patients received immediate postoperative instillation of
chemotherapy.rvival of 164 patients with low and intermediate Ta bladder cancer.
Multivariable
P HR 95% CI P
.001∗ 1.10 1.05–1.15 <.001∗
.68 0.73 0.27–1.98 .54
.25 2.46 0.66–9.16 .17
.42 0.94 0.23–3.77 .94
.26 1.84 0.67–5.00 .23
Ref
.72 0.30 0.05–1.56 .15
.75 0.21 0.02–1.53 .12
.12 2.04 0.32–12.79 .44
.006∗ 0.29 0.09–0.90 .03∗
arch and Treatment of Cancer, HR=hazard ratio.
Figure 2. Kaplan–Meier survival estimates: (A) according to grade; (B)
according to intravesical treatment.
Balan et al. Medicine (2018) 97:16 www.md-journal.comOur study has several limitations. First, the retrospective design
requires further confirmation in prospective cohorts. Second,
patients did not receive immediate postoperative instillation of
chemotherapy, although those at intermediate risk received
adjuvant treatment. Third, we did not perform a central
pathology review on the specimens and did not reassign the
specimens to the latest WHO grading.[31] Also, we did not have
any information on the smoking status of patients, which is a
well-known prognostic factor associated with outcomes in
urothelial carcinomas.[32] Furthermore cancer-specific survival
should have been a primary endpoint, but unfortunately, we did
not have access to death certificates of the patients. Despite these
limitations, this study fulfilled its aim to compare the OS of
patients with newly diagnosed G1 and G2 Ta BC at 10 years after
diagnosis.5. Conclusion
Patients with well differentiated (G1) and moderately well
differentiated (G2) Ta tumors have similar long-term OS after
diagnosis. BCG treatment, even if administered to intermediate
risk cancers, is related to a longer OS.Acknowledgments
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